Lilly Feels Statistical Pain, Withdraws Cymbalta sNDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm will resubmit the application for chronic pain in 2009 along with a recently completed study using FDA’s preferred analysis for patient drop outs.
You may also be interested in...
Lilly’s 2009 Growth Rides On Prasugrel; Advisory Committee’s Review Is Feb. 3
Firm reports ’08 net loss from ImClone deal and Zyprexa settlement
Lilly’s 2009 Growth Rides On Prasugrel; Advisory Committee’s Review Is Feb. 3
Firm reports ’08 net loss from ImClone deal and Zyprexa settlement
Patient Dropouts, Other “Missing Data” To Be Addressed In FDA Guidance
FDA hopes two guidances - one on non-inferiority margins and another on how to handle missing data in clinical trials - will better direct industry in developing clinical trials and extrapolating more accurate data